Public Citizen’s Access to Medicines Experts Are Available to Comment
Public Citizen’s experts are available to comment on this week’s expected consideration of Democratic leadership’s legislation to address soaring prescription prices, H.R. 3, the Lower Drug Costs Now Act of 2019. U.S. House Speaker Nancy Pelosi announced last week that the House will vote on the measure this week.
Public Citizen’s experts can discuss H.R. 3’s details, its capacity to generate savings and key amendments proposed by progressive House members.
Journalists should consider three important resources as they report on H.R. 3:
Below are four experts who are available to speak about the merits, limits and politics of H.R. 3:
Peter Maybarduk, director, Public Citizen’s Access to Medicines Program
firstname.lastname@example.org, c. (202) 390-5375 o. (202) 588-7755
Robert Weissman, president, Public Citizen
Steve Knievel, advocate, Public Citizen’s Access to Medicines Program
email@example.com, (202) 588-7769
Zain Rizvi, law and policy researcher, Public Citizen’s Access to Medicines Program
firstname.lastname@example.org, (202) 588-7774